MedWatch

Swedish bank slashes Novo Nordisk price target ahead of 2022 outlook

Swedish bank Handelsbanken has reduced its share price target for Novo Nordisk by DKK 95 (USD 14.5) due to uncertainties about the pharmaceutical company's forecast for 2022, slated to be publicized on February 2.

Photo: Jacob Gronholt-Pedersen/Reuters/Ritzau Scanpix

Swedish bank Handelsbanken has lowered its share price target for Novo Nordisk from DKK 745 (USD 113.5) to DKK 650 (USD 99), while the bank's recommendation remains on "hold," Handelsbanken reports in an analysis.

The change is due to some reservations about Novo Nordisk's 2022 guidance, which will be publicized in the company's financial report for 2021 on February 2. Expectations therein might be on the lower side, as December brought news of supply issues from a subsupplier, which have meant that Novo Nordisk will only be able to meet demand for the the lowest initial doses of weight loss treatment Wegovy to a limited extent in the first half of 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs